◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

BriaCell Therapeutics Corp.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q4 2025Oct 31, 2025 Q2 2025Apr 30, 2025 Q1 2025Jan 31, 2025 Q4 2024Oct 31, 2024 Q3 2024Jul 31, 2024
Total Revenue 0.00 0.00 0.00 0.00 0.00
Operating Revenue 0.00 0.00 0.00 0.00 0.00
Selling General And Administration 1.6M 1.5M 1.5M 1.5M 1.4M
General And Administrative Expense 1.6M 1.5M 1.5M 1.5M 1.4M
Research And Development 6.7M 4.8M 5.7M 3.7M 4.4M
Operating Expense 8.3M 6.3M 7.2M 5.2M 5.8M
Operating Income -8.3M -6.3M -7.2M -5.2M -5.8M
EBIT -8.3M -6.2M -7.2M -5.2M -5.8M
Interest Expense -- 36,979 -- -- --
Interest Expense Non Operating -- 36,979 -- -- --
Interest Income 48,482 26,632 46,832 13,050 2.00
Interest Income Non Operating 48,482 26,632 46,832 13,050 2.00
Net Interest Income 48,482 -10,347 46,832 13,050 2.00
Other Income Expense -3,867 113,673 784,783 -689,494 4.5M
Gain On Sale Of Security 40,963 176,411 827,367 -617,979 4.6M
Earnings From Equity Interest -44,830 -62,738 -42,584 -71,515 -51,168
Pretax Income -8.3M -6.2M -6.3M -5.8M -1.2M
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -8.2M -6.1M -6.3M -5.8M -1.2M
Net Income From Continuing Operation Net Minority Interest -8.2M -6.1M -6.3M -5.8M -1.2M
Net Income Including Noncontrolling Interests -8.3M -6.2M -6.3M -5.8M -1.2M
Minority Interests 80,763 98,027 46,408 27,101 34,587
Net Income Common Stockholders -8.2M -6.1M -6.3M -5.8M -1.2M
Net Income -8.2M -6.1M -6.3M -5.8M -1.2M
EBITDA -8.3M -6.2M -7.1M -5.1M -5.7M
Normalized EBITDA -8.3M -6.3M -8.0M -4.5M -10.3M
Reconciled Depreciation 26,657 26,656 26,657 26,657 72,444
Basic EPS -4.35 -16.40 -23.30 -32.67 --
Diluted EPS -4.35 -16.40 -23.30 -32.67 --
Basic Average Shares 1.9M 373,551 269,956 177,606 --
Diluted Average Shares 1.9M 373,551 269,956 177,606 --
Total Unusual Items 40,963 176,411 827,367 -617,979 4.6M
Total Unusual Items Excluding Goodwill 40,963 176,411 827,367 -617,979 4.6M
Tax Rate For Calcs 0.00 0.00 0.00 0.00 0.00
Normalized Income -8.2M -6.3M -7.1M -5.2M -5.8M
Average Dilution Earnings -- -- -- 0.00 --
Diluted NI Availto Com Stockholders -8.2M -6.1M -6.3M -5.8M -1.2M
Net Income Continuous Operations -8.3M -6.2M -6.3M -5.8M -1.2M
Net Non Operating Interest Income Expense 48,482 -10,347 46,832 13,050 2.00
Other Gand A 1.6M 1.5M 1.5M 1.5M 1.4M
Total Expenses 8.3M 6.3M 7.2M 5.2M 5.8M
Total Operating Income As Reported -8.3M -6.3M -7.2M -5.2M -5.8M
Line Item Q4 2025Oct 31, 2025 Q2 2025Apr 30, 2025 Q1 2025Jan 31, 2025 Q4 2024Oct 31, 2024 Q3 2024Jul 31, 2024
Cash And Cash Equivalents 2.7M 12.5M 5.0M 5.8M 862,089
Cash Cash Equivalents And Short Term Investments 10.2M 12.5M 5.0M 5.8M 862,089
Other Short Term Investments 7.5M -- -- -- --
Accounts Receivable 1.2M 2.3M 2.1M 2.4M --
Receivables 1.2M 2.3M 2.1M 2.4M 1.4M
Prepaid Assets -- -- -- -- 1.4M
Current Assets 11.3M 14.8M 7.2M 8.2M 3.7M
Gross PPE -- -- -- -- 456,801
Accumulated Depreciation -- -- -- -- -68,626
Net PPE 273,980 319,658 342,497 365,336 388,175
Goodwill And Other Intangible Assets 180,707 188,343 192,160 195,978 199,796
Other Intangible Assets -- -- -- -- 199,796
Investments And Advances 554,448 496,653 454,391 421,975 418,490
Long Term Equity Investment 554,448 496,653 454,391 421,975 418,490
Total Non Current Assets 1.7M 2.2M 2.2M 2.2M 2.2M
Total Assets 13.1M 17.0M 9.4M 10.4M 5.9M
Accounts Payable 2.1M 3.3M 5.0M 4.2M 7.2M
Payables 2.1M 3.3M 5.0M 4.2M 7.2M
Payables And Accrued Expenses 3.3M 4.3M 5.2M 5.0M 7.5M
Current Accrued Expenses 1.2M 1.1M 227,599 754,668 290,376
Current Liabilities 3.3M 4.3M 5.2M 5.0M 7.5M
Total Non Current Liabilities Net Minority Interest 406,873 730,012 905,838 1.7M 1.1M
Total Liabilities Net Minority Interest 3.7M 5.1M 6.1M 6.7M 8.6M
Common Stock 101.7M 94.0M 85.5M 82.0M 72.2M
Capital Stock 101.7M 94.0M 85.5M 82.0M 72.2M
Retained Earnings -120.0M -103.7M -97.5M -91.2M -85.4M
Gains Losses Not Affecting Retained Earnings -138,684 -138,684 -138,684 -138,684 -138,684
Other Equity Adjustments -138,684 -138,684 -138,684 -138,684 -138,684
Common Stock Equity 10.0M 12.4M 3.6M 4.0M -2.4M
Stockholders Equity 10.0M 12.4M 3.6M 4.0M -2.4M
Total Equity Gross Minority Interest 9.4M 11.9M 3.2M 3.7M -2.7M
Minority Interest -627,558 -474,058 -376,031 -329,623 -302,522
Total Capitalization 10.0M 12.4M 3.6M 4.0M -2.4M
Net Tangible Assets 9.8M 12.2M 3.4M 3.8M -2.6M
Tangible Book Value 9.8M 12.2M 3.4M 3.8M -2.6M
Working Capital 8.0M 10.5M 1.9M 3.2M -3.8M
Invested Capital 10.0M 12.4M 3.6M 4.0M -2.4M
Share Issued 1.9M 655,809 294,694 241,221 121,897
Ordinary Shares Number 1.9M 655,809 294,694 241,221 121,897
Derivative Product Liabilities 406,873 730,012 905,838 1.7M 1.1M
Investmentsin Subsidiariesat Cost 554,448 496,653 454,391 421,975 418,490
Non Current Prepaid Assets 717,508 1.2M 1.2M 1.2M 1.2M
Other Equity Interest 28.3M 22.2M 15.8M 13.4M 11.0M
Other Properties -- -- -- -- 456,801
Other Receivables -- -- -- -- 1.4M
Line Item Q4 2025Oct 31, 2025 Q2 2025Apr 30, 2025 Q1 2025Jan 31, 2025 Q4 2024Oct 31, 2024 Q3 2024Jul 31, 2024
Operating Cash Flow -7.7M -7.2M -5.9M -7.0M -4.0M
Cash Flow From Continuing Operating Activities -7.7M -7.2M -5.9M -7.0M -4.0M
Depreciation And Amortization 26,657 26,656 26,657 26,657 72,444
Depreciation Amortization Depletion 26,657 26,656 26,657 26,657 72,444
Stock Based Compensation 294,686 224,815 285,093 266,971 377,892
Change In Working Capital 227,645 -1.1M 870,113 -2.1M 1.3M
Change In Receivables 887,860 9,943 358,237 364,935 -736,218
Change In Payables And Accrued Expense -660,215 -900,205 592,202 -2.5M 703,400
Change In Payable -1.2M -1.7M 769,271 -2.9M 748,379
Other Non Cash Items -89,487 -- -- -- --
Purchase Of Business -75,000 -105,000 -75,000 -75,000 0.00
Investing Cash Flow -75,000 -105,000 -75,000 -75,000 -456,801
Cash Flow From Continuing Investing Activities -75,000 -105,000 -75,000 -75,000 -456,801
Issuance Of Capital Stock 0.00 14.7M 4.7M 11.7M --
Repurchase Of Capital Stock -- -- -- -- 0.00
Net Common Stock Issuance 0.00 14.7M 4.7M 11.7M 4.4M
Common Stock Payments -- -- -- -- 0.00
Financing Cash Flow 0.00 14.7M 5.2M 12.0M 4.4M
Cash Flow From Continuing Financing Activities 0.00 14.7M 5.2M 12.0M 4.4M
Changes In Cash -7.8M 7.4M -778,611 4.9M -73,605
Beginning Cash Position 10.5M 5.0M 5.8M 862,089 935,694
End Cash Position 2.7M 12.5M 5.0M 5.8M 862,089
Free Cash Flow -7.7M -7.2M -5.9M -7.0M -4.5M
Amortization Cash Flow 3,818 -- -- 3,818 --
Amortization Of Intangibles 3,818 -- -- 3,818 --
Change In Account Payable -1.2M -1.7M 769,271 -2.9M 748,379
Change In Accrued Expense 494,573 823,830 -177,069 464,292 -44,979
Change In Prepaid Assets -- -185,969 291,527 -371,853 1.3M
Common Stock Issuance 0.00 14.7M 4.7M 11.7M --
Depreciation 22,839 -- -- 22,839 --
Earnings Losses From Equity Investments 44,830 62,738 42,584 71,515 51,168
Gain Loss On Investment Securities 69,201 -175,826 -806,841 616,643 -4.6M
Net Business Purchase And Sale -75,000 -105,000 -75,000 -75,000 0.00
Net Income From Continuing Operations -8.3M -6.2M -6.3M -5.8M -1.2M
Operating Gains Losses 114,031 -113,088 -764,257 688,158 -4.5M
Proceeds From Stock Option Exercised 0.00 0.00 527,764 293,251 0.00
NEWS
Loading news...
TRENDING
Loading...